Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Escherichia coli | penicillin-binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Mycobacterium tuberculosis | Possible penicillin-binding protein | Get druggable targets OG5_149948 | All targets in OG5_149948 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.3795 | 1 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.3795 | 1 | 1 |
Mycobacterium ulcerans | carboxylesterase, LipT | 0.0641 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.3795 | 1 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0641 | 0 | 0.5 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.3795 | 1 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.3795 | 1 | 1 |
Onchocerca volvulus | 0.0641 | 0 | 0.5 | |
Brugia malayi | Carboxylesterase family protein | 0.3795 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.3795 | 1 | 1 |
Onchocerca volvulus | 0.0641 | 0 | 0.5 | |
Onchocerca volvulus | 0.0641 | 0 | 0.5 | |
Echinococcus granulosus | acetylcholinesterase | 0.3795 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.3795 | 1 | 1 |
Onchocerca volvulus | 0.0641 | 0 | 0.5 | |
Echinococcus granulosus | acetylcholinesterase | 0.3795 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.3795 | 1 | 1 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0641 | 0 | 0.5 |
Trichomonas vaginalis | carboxylesterase domain containing protein, putative | 0.0641 | 0 | 0.5 |
Mycobacterium tuberculosis | Carboxylesterase LipT | 0.0641 | 0 | 0.5 |
Echinococcus granulosus | carboxylesterase 5A | 0.3795 | 1 | 1 |
Onchocerca volvulus | 0.0641 | 0 | 0.5 | |
Trichomonas vaginalis | spcc417.12 protein, putative | 0.0641 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | > 50 um | PUBCHEM_BIOASSAY: Estrogen Receptor-beta Coactivator Binding Inhibitors Dose Response Confirmation. (Class of assay: confirmatory) [Related pubchem assays: 633 (Primary screen preceding this dose response confirmation assay.)] | ChEMBL. | No reference |
Potency (functional) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS of alpha-syn Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.